The 2 analysts offering 12-month price forecasts for Cidara Therapeutics Inc have a median target of 4.50, with a high estimate of 6.00 and a low estimate of 3.00. The median estimate represents a +477.00% increase from the last price of 0.78.
The current consensus among 3 polled investment analysts is to Buy stock in Cidara Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.07
Reporting Date Feb 28
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.